Form 4 OKYO Pharma Ltd For: 29 July
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- EspaƱol (EspaƱa)
- EspaƱol (MƩxico)
- FranƧais
- Italiano
- Nederlands
- Polski
- PortuguĆŖs (Portugal)
- PortuguĆŖs (Brasil)
- Š ŃŃŃŠŗŠøŠ¹
- TĆ¼rkƧe
- āŲ§ŁŲ¹Ų±ŲØŁŲ©ā
- ĪĪ»Ī»Ī·Ī½Ī¹ĪŗĪ¬
- Svenska
- Suomi
- ×¢××Ø××Ŗ
- ę„ę¬čŖ
- ķźµģ“
- ē®ä½äøę
- ē¹é«äøę
- Bahasa Indonesia
- Bahasa Melayu
- ą¹ąøąø¢
- Tiįŗæng Viį»t
- ą¤¹ą¤æą¤ą¤¦ą„
OKYO Pharma (OKYO)
The OKYO Pharma Ltd share price today is 1.500, view NASDAQ OKYO stock exchange data. Track the latest OKYO Pharma Ltd share price with real-time updates on OKYO stock performance including market cap, day range, 52-week range and dividend yield. Access OKYO charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.490
1.560
52 wk Range
1.340
3.200
Earnings results expected in 8 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.4901.560
52 wk Range
1.3403.200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
OKYO Scorecard
Companyās Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
8.333
Upside
+455.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
OKYO Pharma CSO purchases additional shares at $1.49- Investing.com
OKYO Pharma director buys 3,500 shares at $1.40 each- Investing.com
- Form 4 OKYO Pharma Ltd For: 29 July
- Investing.com
- OKYO Pharma CSO purchases additional shares at $1.49
- Investing.com
Form 4 OKYO Pharma Ltd For: 24 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.333
(+455.56% Upside)
Earnings
Latest Release
03-06-2026
EPS / Forecast
-0.03 / -0.08
Revenue / Forecast
-- / --
Compare OKYO to Peers and Sector
Metrics to compare | OKYO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOKYOPeersSector | |
|---|---|---|---|---|
P/E Ratio | ā8.8x | ā1.9x | ā0.4x | |
PEG Ratio | 0.09 | 0.05 | 0.00 | |
Price/Book | 6.4x | 4.5x | 2.6x | |
Price / LTM Sales | - | 6.7x | 3.1x | |
Upside (Analyst Target) | 363.6% | 95.1% | 49.3% | |
Fair Value Upside | Unlock | 9.5% | 6.7% | Unlock |
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the OKYO Pharma Ltd (OKYO) Share Price Today?
The OKYO Pharma Ltd share price today is 1.500.
What is the current OKYO Pharma Ltd (OKYO) share price and day range?
As of 25-08-2026, the OKYO Pharma Ltd share price is 1.500, with a previous close of 1.540. The share price has ranged from 1.490 to 1.560 today, while the 52-week range spans from 1.340 to 3.200.
What Is the OKYO Pharma Ltd Market Cap?
As of today, OKYO Pharma Ltd market cap is 78.720M.
What Is the OKYO Pharma Ltd (OKYO) Share Price Target?
The average 12-month share price target for OKYO Pharma Ltd is 8.333, with a high estimate of 13 and a low estimate of 5. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +455.56% Upside potential.
What Is OKYO Pharma Ltd's Earnings Per Share (TTM)?
The OKYO Pharma Ltd EPS (TTM) is -0.240.
When Is the Next OKYO Pharma Ltd Earnings Date?
OKYO Pharma Ltd will release its next earnings report on 02-09-2026.
From a Technical Analysis Perspective, Is OKYO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does OKYO Pharma Ltd Trade On?
OKYO Pharma Ltd is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for OKYO Pharma Ltd?
The stock symbol for OKYO Pharma Ltd is "OKYO."
How Many Times Has OKYO Pharma Ltd Stock Split?
OKYO Pharma Ltd has split 2 times.
How Many Employees Does OKYO Pharma Ltd Have?
OKYO Pharma Ltd has 5 employees.
What Is the OKYO After Hours Price?
OKYO's last after hours stock price is 1.481, the stock has changed by -0.019, or -1.250%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion MediaĀ would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are notĀ necessarilyĀ provided by any market or exchange, but may be provided byĀ market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.Ā Fusion MediaĀ andĀ any provider of the data contained in this websiteĀ will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion MediaĀ would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are notĀ necessarilyĀ provided by any market or exchange, but may be provided byĀ market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.Ā Fusion MediaĀ andĀ any provider of the data contained in this websiteĀ will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Ā© 2007-2026 - Fusion Media Limited. All Rights Reserved.